FIG. 3.

Glucocorticoid receptor antagonist RU-486 blocks MT expression in both the liver and lungs of wild-type and IL-6 null mice. (A) Nucleotide sequence upstream of the MT-II promoter that spans two GREs. RU-486 or vehicle was injected subcutaneously into C57BL/6 and IL-6 knockout mice every day starting 1 day before infection. The animals were sacrificed on day 5, and RNA from the liver and lung was analyzed for MT-I, MT-II, and GAPDH levels as described for Fig. 2. (B and D) Northern blot analysis of MT in wild-type and null IL-6 mice with and without RU-486 treatment. (C and E) Quantitative analysis of Northern blot data. The data presented are the means of three independent experiments ± SEM.